Preeclampsia laboratory testing market size to grow by USD 785.73 million between 2022 and 2027; Growth driven by increasing incidence of preterm births – Technavio

The preeclampsia laboratory testing market size is set to grow by USD 785.73 million between 2022 and 2027 and register a CAGR of 8%, according to Technavio’s latest market research report estimates. With a focus on identifying dominant industry influencers, Technavio’s reports present a detailed study by way of synthesis and summation of data from multiple sources. This report offers an up-to-date analysis of the current market scenario, the latest trends and drivers, and the overall market environment. View a Sample Report.

Though the increasing incidence of preterm births, market expansion in emerging economies, and rising number of gynecology clinics will offer immense growth opportunities. To leverage the current opportunities, market vendors must strengthen their foothold in the fast-growing segments while maintaining their positions in the slow-growing segments.

Preeclampsia Laboratory Testing Market 2023-2027: Segmentation

  • Product Type
    • Consumables
    • Instruments
  • Test
    • Blood test
    • Urine test
    • Others
  • Geography
    • North America
    • Europe
    • Asia
    • Rest Of World (ROW)

The market growth in the consumables segment will be significant over the forecast period. Consumables are used in the selection and enrichment of preeclampsia laboratory testing procedures. The low cost and high usage frequency of consumables are driving the growth of the segment. In addition, many governments across the world are providing grants for the R&D of consumables. This is another major factor driving the segment growth.

North America will account for 38% of the market growth during the forecast period. The growth of the regional market is driven by improvements in drug and vaccine discovery and development, advances in biotechnology and pharmaceutical research, and the presence of several vendors. Increasing budgets of government and private hospitals, the proliferation of hospitals and maternity centers, increasing neonatal mortality rate, and the growing demand for high-tech pregnancy screening devices and maternity care facilities are other key factors driving the growth of the preeclampsia laboratory testing market in North America.

Download our market sample report now to gain access to a detailed analysis of the preeclampsia laboratory testing market.

Preeclampsia Laboratory Testing Market 2023-2027: Vendor Analysis and Scope

The global preeclampsia laboratory testing market is fragmented, with the presence of several vendors. The vendors in the market are adopting various growth strategies such as new product launches, strategic alliances, and mergers and acquisitions to remain competitive. The moderate market growth potential and access to distribution channels encourage new players to enter the market. However, stringent regulations and product patents hinder the entry of new vendors. Also, the high capital requirements and low economies of scale make it difficult for new players to enter the market. Thus, the threat of new entrants was moderate in 2022 and is expected to remain the same during the forecast period. Some of the key vendors covered in the report include:

  • ACON Laboratories Inc. – The company offers preeclampsia laboratory testing, such as Distinct Early Detection Pregnancy Test.
  • BioCheck Inc. – The company offers preeclampsia laboratory testing, such as Lyphochek Fertility Control.
  • bioMerieux SA – The company offers preeclampsia laboratory testing under the brand DRG INSTRUMENTS GMBH.
  • Biora Therapeutics Inc. – The company offers preeclampsia laboratory testing, such as the VIDAS ToRC panel.
  • Bio Rad Laboratories Inc.
  • Cardinal Health Inc.
  • Diabetomics Inc.
  • F. Hoffmann La Roche Ltd.
  • GestVision Inc.
  • Lifeassay Diagnostics Pty Ltd.
  • MedGyn Products Inc.
  • Metabolomic Diagnostics
  • MOMM Diagnostics
  • Perkin Elmer Inc.
  • Quidel Corp.

Why Buy?

  • Add credibility to strategy
  • Analyzes competitor’s offerings
  • Get a holistic view of the market

Make your profit margin bigger and better with Technavio’s expert analysis – Buy the Report

The report also covers the following areas:

Preeclampsia Laboratory Testing Market 2023-2027: Market Dynamics

  • Driver – The market is driven by the increasing incidence of preterm births. The number of preemptive births has increased at a rapid rate globally over recent years. The incidence of the condition is increasing in developing countries such as China and India due to medically unnecessary inductions and cesarean deliveries before full term. In less-developed countries such as Bangladesh, Afghanistan, and Central Africa, the main causes of preterm births include infections, malaria, and high adolescent pregnancy rates. The rising incidence of the condition is increasing the adoption of preeclampsia laboratory testing, thereby driving market growth.
  • Trend – The growing need for companion diagnostics is identified as the key trend in the market. The demand for companion diagnostics is increasing, with the growing need for understanding patient requirements and providing personalized medicines. This trend is gaining more popularity and is expected to create a good opportunity to penetrate POC products, including preeclampsia laboratory testing products, into new markets. This results in improved disease management, treatment adherence, and patient satisfaction. All these factors will positively influence the market growth over the forecast period.
  • Challenge – The lack of reimbursement will challenge the growth of the market during the forecast period. Most health insurance policies do not cover reimbursement for preeclampsia laboratory testing. The unavailability of reimbursement cover and the high cost serve as barriers to the adoption of preeclampsia laboratory testing. Several state and federal agents and healthcare officials have publicly encouraged payers to revise insurance policies for preeclampsia laboratory testing. However, the market still lacks the availability of reimbursement services with respect to preeclampsia laboratory testing. Such factors restrict the growth of the market in focus.

Gain instant access to 17,000+ market research reports and world-class market
intelligence.

Technavio’s SUBSCRIPTION platform

Preeclampsia Laboratory Testing Market 2023-2027: Key Highlights

  • CAGR of the market during the forecast period 2023-2027
  • Detailed information on factors that will assist preeclampsia laboratory testing market growth during the next five years
  • Estimation of the preeclampsia laboratory testing market size and its contribution to the parent market
  • Predictions on upcoming trends and changes in consumer behavior
  • The growth of the preeclampsia laboratory testing market
  • Analysis of the market’s competitive landscape and detailed information on vendors
  • Comprehensive details of factors that will challenge the growth of preeclampsia laboratory testing market vendors

Related Reports:

The laboratory analytical instruments and consumables market size is estimated to grow at a CAGR of 8.41% between 2022 and 2027. The laboratory analytical instruments and consumables market size is forecasted to increase by USD 15.99 billion. The market is segmented by application (element analysis, separation analysis, and molecular analysis), product (laboratory analytical instruments and consumables), and geography (North America, Europe, Asia, and Rest of World (ROW)).

The microbiological testing of water market is estimated to grow at a CAGR of 7.3% between 2022 and 2027. The size of the market is forecasted to increase by USD 684.78 million. The market is segmented by type (instruments, reagents, and test kits), end-user (pharmaceutical, clinical, food, energy, and others), and geography (North America, Europe, Asia, and Rest of World (ROW)).

Preeclampsia Laboratory Testing Market Scope

Report Coverage

Details

Base year

2022

Historic period

2017-2021

Forecast period

2023-2027

Growth momentum & CAGR

Accelerate at a CAGR of 8%

Market growth 2023-2027

USD 785.73 million

Market structure

Fragmented

YoY growth 2022-2023(%)

7.45

Regional analysis

North America, Europe, Asia, and Rest of World (ROW)

Performing market contribution

North America at 38%

Key countries

US, Germany, UK, China, and India

Competitive landscape

Leading Vendors, Market Positioning of Vendors, Competitive Strategies, and Industry Risks

Key companies profiled

Abbott Laboratories, ACON Laboratories Inc., Bio Rad Laboratories Inc., BioCheck Inc., bioMerieux SA, Biora Therapeutics Inc., Cardinal Health Inc., Diabetomics Inc., F. Hoffmann La Roche Ltd., GestVision Inc., Lifeassay Diagnostics Pty Ltd., MedGyn Products Inc., Metabolomic Diagnostics, MOMM Diagnostics, Perkin Elmer Inc., Quidel Corp., Sera Prognostics Inc., Siemens AG, Thermo Fisher Scientific Inc., and Avecon Healthcare Pvt. Ltd.

Market dynamics

Parent market analysis, market growth inducers and obstacles, fast-growing and slow-growing segment analysis, COVID-19 impact and recovery analysis and future consumer dynamics, and market condition analysis for the forecast period.

Customization purview

If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized.

Browse through Technavio’s Health Care Market Reports

Table of contents:

1 Executive Summary

  • 1.1 Market overview
    • Exhibit 01: Executive Summary – Chart on Market Overview
    • Exhibit 02: Executive Summary – Data Table on Market Overview
    • Exhibit 03: Executive Summary – Chart on Global Market Characteristics
    • Exhibit 04: Executive Summary – Chart on Market by Geography
    • Exhibit 05: Executive Summary – Chart on Market Segmentation by Product Type
    • Exhibit 06: Executive Summary – Chart on Market Segmentation by Test
    • Exhibit 07: Executive Summary – Chart on Incremental Growth
    • Exhibit 08: Executive Summary – Data Table on Incremental Growth
    • Exhibit 09: Executive Summary – Chart on Vendor Market Positioning

2 Market Landscape

  • 2.1 Market ecosystem
    • Exhibit 10: Parent market
    • Exhibit 11: Market Characteristics

3 Market Sizing

  • 3.1 Market definition
    • Exhibit 12: Offerings of vendors included in the market definition
  • 3.2 Market segment analysis
    • Exhibit 13: Market segments
  • 3.3 Market size 2022
  • 3.4 Market outlook: Forecast for 2022-2027
    • Exhibit 14: Chart on Global – Market size and forecast 2022-2027 ($ million)
    • Exhibit 15: Data Table on Global – Market size and forecast 2022-2027 ($ million)
    • Exhibit 16: Chart on Global Market: Year-over-year growth 2022-2027 (%)
    • Exhibit 17: Data Table on Global Market: Year-over-year growth 2022-2027 (%)

4 Historic Market Size

  • 4.1 Global preeclampsia laboratory testing market 2017 – 2021
    • Exhibit 18: Historic Market Size – Data Table on Global preeclampsia laboratory testing market 2017 – 2021 ($ million)
  • 4.2 Product Type Segment Analysis 2017 – 2021
    • Exhibit 19: Historic Market Size – Product Type Segment 2017 – 2021 ($ million)
  • 4.3 Test Segment Analysis 2017 – 2021
    • Exhibit 20: Historic Market Size – Test Segment 2017 – 2021 ($ million)
  • 4.4 Geography Segment Analysis 2017 – 2021
    • Exhibit 21: Historic Market Size – Geography Segment 2017 – 2021 ($ million)
  • 4.5 Country Segment Analysis 2017 – 2021
    • Exhibit 22: Historic Market Size – Country Segment 2017 – 2021 ($ million)

5 Five Forces Analysis

  • 5.1 Five forces summary
    • Exhibit 23: Five forces analysis – Comparison between 2022 and 2027
  • 5.2 Bargaining power of buyers
    • Exhibit 24: Chart on Bargaining power of buyers – Impact of key factors 2022 and 2027
  • 5.3 Bargaining power of suppliers
    • Exhibit 25: Bargaining power of suppliers – Impact of key factors in 2022 and 2027
  • 5.4 Threat of new entrants
    • Exhibit 26: Threat of new entrants – Impact of key factors in 2022 and 2027
  • 5.5 Threat of substitutes
    • Exhibit 27: Threat of substitutes – Impact of key factors in 2022 and 2027
  • 5.6 Threat of rivalry
    • Exhibit 28: Threat of rivalry – Impact of key factors in 2022 and 2027
  • 5.7 Market condition
    • Exhibit 29: Chart on Market condition – Five forces 2022 and 2027

6 Market Segmentation by Product Type

  • 6.1 Market segments
    • Exhibit 30: Chart on Product Type – Market share 2022-2027 (%)
    • Exhibit 31: Data Table on Product Type – Market share 2022-2027 (%)
  • 6.2 Comparison by Product Type
    • Exhibit 32: Chart on Comparison by Product Type
    • Exhibit 33: Data Table on Comparison by Product Type
  • 6.3 Consumables – Market size and forecast 2022-2027
    • Exhibit 34: Chart on Consumables – Market size and forecast 2022-2027 ($ million)
    • Exhibit 35: Data Table on Consumables – Market size and forecast 2022-2027 ($ million)
    • Exhibit 36: Chart on Consumables – Year-over-year growth 2022-2027 (%)
    • Exhibit 37: Data Table on Consumables – Year-over-year growth 2022-2027 (%)
  • 6.4 Instruments – Market size and forecast 2022-2027
    • Exhibit 38: Chart on Instruments – Market size and forecast 2022-2027 ($ million)
    • Exhibit 39: Data Table on Instruments – Market size and forecast 2022-2027 ($ million)
    • Exhibit 40: Chart on Instruments – Year-over-year growth 2022-2027 (%)
    • Exhibit 41: Data Table on Instruments – Year-over-year growth 2022-2027 (%)
  • 6.5 Market opportunity by Product Type
    • Exhibit 42: Market opportunity by Product Type ($ million)
    • Exhibit 43: Data Table on Market opportunity by Product Type ($ million)

7 Market Segmentation by Test

  • 7.1 Market segments
    • Exhibit 44: Chart on Test – Market share 2022-2027 (%)
    • Exhibit 45: Data Table on Test – Market share 2022-2027 (%)
  • 7.2 Comparison by Test
    • Exhibit 46: Chart on Comparison by Test
    • Exhibit 47: Data Table on Comparison by Test
  • 7.3 Blood test – Market size and forecast 2022-2027
    • Exhibit 48: Chart on Blood test – Market size and forecast 2022-2027 ($ million)
    • Exhibit 49: Data Table on Blood test – Market size and forecast 2022-2027 ($ million)
    • Exhibit 50: Chart on Blood test – Year-over-year growth 2022-2027 (%)
    • Exhibit 51: Data Table on Blood test – Year-over-year growth 2022-2027 (%)
  • 7.4 Urine test – Market size and forecast 2022-2027
    • Exhibit 52: Chart on Urine test – Market size and forecast 2022-2027 ($ million)
    • Exhibit 53: Data Table on Urine test – Market size and forecast 2022-2027 ($ million)
    • Exhibit 54: Chart on Urine test – Year-over-year growth 2022-2027 (%)
    • Exhibit 55: Data Table on Urine test – Year-over-year growth 2022-2027 (%)
  • 7.5 Others – Market size and forecast 2022-2027
    • Exhibit 56: Chart on Others – Market size and forecast 2022-2027 ($ million)
    • Exhibit 57: Data Table on Others – Market size and forecast 2022-2027 ($ million)
    • Exhibit 58: Chart on Others – Year-over-year growth 2022-2027 (%)
    • Exhibit 59: Data Table on Others – Year-over-year growth 2022-2027 (%)
  • 7.6 Market opportunity by Test
    • Exhibit 60: Market opportunity by Test ($ million)
    • Exhibit 61: Data Table on Market opportunity by Test ($ million)

8 Customer Landscape

  • 8.1 Customer landscape overview
    • Exhibit 62: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria

9 Geographic Landscape

  • 9.1 Geographic segmentation
    • Exhibit 63: Chart on Market share by geography 2022-2027 (%)
    • Exhibit 64: Data Table on Market share by geography 2022-2027 (%)
  • 9.2 Geographic comparison
    • Exhibit 65: Chart on Geographic comparison
    • Exhibit 66: Data Table on Geographic comparison
  • 9.3 North America – Market size and forecast 2022-2027
    • Exhibit 67: Chart on North America – Market size and forecast 2022-2027 ($ million)
    • Exhibit 68: Data Table on North America – Market size and forecast 2022-2027 ($ million)
    • Exhibit 69: Chart on North America – Year-over-year growth 2022-2027 (%)
    • Exhibit 70: Data Table on North America – Year-over-year growth 2022-2027 (%)
  • 9.4 Europe – Market size and forecast 2022-2027
    • Exhibit 71: Chart on Europe – Market size and forecast 2022-2027 ($ million)
    • Exhibit 72: Data Table on Europe – Market size and forecast 2022-2027 ($ million)
    • Exhibit 73: Chart on Europe – Year-over-year growth 2022-2027 (%)
    • Exhibit 74: Data Table on Europe – Year-over-year growth 2022-2027 (%)
  • 9.5 Asia – Market size and forecast 2022-2027
    • Exhibit 75: Chart on Asia – Market size and forecast 2022-2027 ($ million)
    • Exhibit 76: Data Table on Asia – Market size and forecast 2022-2027 ($ million)
    • Exhibit 77: Chart on Asia – Year-over-year growth 2022-2027 (%)
    • Exhibit 78: Data Table on Asia – Year-over-year growth 2022-2027 (%)
  • 9.6 Rest of World (ROW) – Market size and forecast 2022-2027
    • Exhibit 79: Chart on Rest of World (ROW) – Market size and forecast 2022-2027 ($ million)
    • Exhibit 80: Data Table on Rest of World (ROW) – Market size and forecast 2022-2027 ($ million)
    • Exhibit 81: Chart on Rest of World (ROW) – Year-over-year growth 2022-2027 (%)
    • Exhibit 82: Data Table on Rest of World (ROW) – Year-over-year growth 2022-2027 (%)
  • 9.7 US – Market size and forecast 2022-2027
    • Exhibit 83: Chart on US – Market size and forecast 2022-2027 ($ million)
    • Exhibit 84: Data Table on US – Market size and forecast 2022-2027 ($ million)
    • Exhibit 85: Chart on US – Year-over-year growth 2022-2027 (%)
    • Exhibit 86: Data Table on US – Year-over-year growth 2022-2027 (%)
  • 9.8 Germany – Market size and forecast 2022-2027
    • Exhibit 87: Chart on Germany – Market size and forecast 2022-2027 ($ million)
    • Exhibit 88: Data Table on Germany – Market size and forecast 2022-2027 ($ million)
    • Exhibit 89: Chart on Germany – Year-over-year growth 2022-2027 (%)
    • Exhibit 90: Data Table on Germany – Year-over-year growth 2022-2027 (%)
  • 9.9 China – Market size and forecast 2022-2027
    • Exhibit 91: Chart on China – Market size and forecast 2022-2027 ($ million)
    • Exhibit 92: Data Table on China – Market size and forecast 2022-2027 ($ million)
    • Exhibit 93: Chart on China – Year-over-year growth 2022-2027 (%)
    • Exhibit 94: Data Table on China – Year-over-year growth 2022-2027 (%)
  • 9.10 UK – Market size and forecast 2022-2027
    • Exhibit 95: Chart on UK – Market size and forecast 2022-2027 ($ million)
    • Exhibit 96: Data Table on UK – Market size and forecast 2022-2027 ($ million)
    • Exhibit 97: Chart on UK – Year-over-year growth 2022-2027 (%)
    • Exhibit 98: Data Table on UK – Year-over-year growth 2022-2027 (%)
  • 9.11 India – Market size and forecast 2022-2027
    • Exhibit 99: Chart on India – Market size and forecast 2022-2027 ($ million)
    • Exhibit 100: Data Table on India – Market size and forecast 2022-2027 ($ million)
    • Exhibit 101: Chart on India – Year-over-year growth 2022-2027 (%)
    • Exhibit 102: Data Table on India – Year-over-year growth 2022-2027 (%)
  • 9.12 Market opportunity by geography
    • Exhibit 103: Market opportunity by geography ($ million)
    • Exhibit 104: Data Tables on Market opportunity by geography ($ million)

10 Drivers, Challenges, and Trends

  • 10.1 Market drivers
  • 10.2 Market challenges
  • 10.3 Impact of drivers and challenges
    • Exhibit 105: Impact of drivers and challenges in 2022 and 2027
  • 10.4 Market trends

11 Vendor Landscape

  • 11.1 Overview
  • 11.2 Vendor landscape
    • Exhibit 106: Overview on Criticality of inputs and Factors of differentiation
  • 11.3 Landscape disruption
    • Exhibit 107: Overview on factors of disruption
  • 11.4 Industry risks
    • Exhibit 108: Impact of key risks on business

12 Vendor Analysis

  • 12.1 Vendors covered
    • Exhibit 109: Vendors covered
  • 12.2 Market positioning of vendors
    • Exhibit 110: Matrix on vendor position and classification
  • 12.3 Abbott Laboratories
    • Exhibit 111: Abbott Laboratories – Overview
    • Exhibit 112: Abbott Laboratories – Business segments
    • Exhibit 113: Abbott Laboratories – Key news
    • Exhibit 114: Abbott Laboratories – Key offerings
    • Exhibit 115: Abbott Laboratories – Segment focus
  • 12.4 ACON Laboratories Inc.
    • Exhibit 116: ACON Laboratories Inc. – Overview
    • Exhibit 117: ACON Laboratories Inc. – Product / Service
    • Exhibit 118: ACON Laboratories Inc. – Key offerings
  • 12.5 Bio Rad Laboratories Inc.
    • Exhibit 119: Bio Rad Laboratories Inc. – Overview
    • Exhibit 120: Bio Rad Laboratories Inc. – Business segments
    • Exhibit 121: Bio Rad Laboratories Inc. – Key news
    • Exhibit 122: Bio Rad Laboratories Inc. – Key offerings
    • Exhibit 123: Bio Rad Laboratories Inc. – Segment focus
  • 12.6 BioCheck Inc.
    • Exhibit 124: BioCheck Inc. – Overview
    • Exhibit 125: BioCheck Inc. – Product / Service
    • Exhibit 126: BioCheck Inc. – Key offerings
  • 12.7 bioMerieux SA
    • Exhibit 127: bioMerieux SA – Overview
    • Exhibit 128: bioMerieux SA – Product / Service
    • Exhibit 129: bioMerieux SA – Key offerings
  • 12.8 Biora Therapeutics Inc.
    • Exhibit 130: Biora Therapeutics Inc. – Overview
    • Exhibit 131: Biora Therapeutics Inc. – Product / Service
    • Exhibit 132: Biora Therapeutics Inc. – Key offerings
  • 12.9 Cardinal Health Inc.
    • Exhibit 133: Cardinal Health Inc. – Overview
    • Exhibit 134: Cardinal Health Inc. – Business segments
    • Exhibit 135: Cardinal Health Inc. – Key news
    • Exhibit 136: Cardinal Health Inc. – Key offerings
    • Exhibit 137: Cardinal Health Inc. – Segment focus
  • 12.10 Diabetomics Inc.
    • Exhibit 138: Diabetomics Inc. – Overview
    • Exhibit 139: Diabetomics Inc. – Product / Service
    • Exhibit 140: Diabetomics Inc. – Key offerings
  • 12.11 F. Hoffmann La Roche Ltd.
    • Exhibit 141: F. Hoffmann La Roche Ltd. – Overview
    • Exhibit 142: F. Hoffmann La Roche Ltd. – Business segments
    • Exhibit 143: F. Hoffmann La Roche Ltd. – Key news
    • Exhibit 144: F. Hoffmann La Roche Ltd. – Key offerings
    • Exhibit 145: F. Hoffmann La Roche Ltd. – Segment focus
  • 12.12 MedGyn Products Inc.
    • Exhibit 146: MedGyn Products Inc. – Overview
    • Exhibit 147: MedGyn Products Inc. – Product / Service
    • Exhibit 148: MedGyn Products Inc. – Key offerings
  • 12.13 Metabolomic Diagnostics
    • Exhibit 149: Metabolomic Diagnostics – Overview
    • Exhibit 150: Metabolomic Diagnostics – Product / Service
    • Exhibit 151: Metabolomic Diagnostics – Key offerings
  • 12.14 Perkin Elmer Inc.
    • Exhibit 152: Perkin Elmer Inc. – Overview
    • Exhibit 153: Perkin Elmer Inc. – Business segments
    • Exhibit 154: Perkin Elmer Inc. – Key news
    • Exhibit 155: Perkin Elmer Inc. – Key offerings
    • Exhibit 156: Perkin Elmer Inc. – Segment focus
  • 12.15 Sera Prognostics Inc.
    • Exhibit 157: Sera Prognostics Inc. – Overview
    • Exhibit 158: Sera Prognostics Inc. – Product / Service
    • Exhibit 159: Sera Prognostics Inc. – Key offerings
  • 12.16 Siemens AG
    • Exhibit 160: Siemens AG – Overview
    • Exhibit 161: Siemens AG – Business segments
    • Exhibit 162: Siemens AG – Key news
    • Exhibit 163: Siemens AG – Key offerings
    • Exhibit 164: Siemens AG – Segment focus
  • 12.17 Thermo Fisher Scientific Inc.
    • Exhibit 165: Thermo Fisher Scientific Inc. – Overview
    • Exhibit 166: Thermo Fisher Scientific Inc. – Business segments
    • Exhibit 167: Thermo Fisher Scientific Inc. – Key news
    • Exhibit 168: Thermo Fisher Scientific Inc. – Key offerings
    • Exhibit 169: Thermo Fisher Scientific Inc. – Segment focus

13 Appendix

  • 13.1 Scope of the report
  • 13.2 Inclusions and exclusions checklist
    • Exhibit 170: Inclusions checklist
    • Exhibit 171: Exclusions checklist
  • 13.3 Currency conversion rates for US$
    • Exhibit 172: Currency conversion rates for US$
  • 13.4 Research methodology
    • Exhibit 173: Research methodology
    • Exhibit 174: Validation techniques employed for market sizing
    • Exhibit 175: Information sources
  • 13.5 List of abbreviations
    • Exhibit 176: List of abbreviations

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”